Market capitalization | $668.27m |
Enterprise Value | $551.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 89.43 |
P/S ratio (TTM) P/S ratio | 108.31 |
P/B ratio (TTM) P/B ratio | 6.81 |
Revenue growth (TTM) Revenue growth | -65.98% |
Revenue (TTM) Revenue | $6.17m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
4 Analysts have issued a Arbutus Biopharma Corporation forecast:
4 Analysts have issued a Arbutus Biopharma Corporation forecast:
Dec '24 |
+/-
%
|
||
Revenue | 6.17 6.17 |
66%
66%
|
|
Gross Profit | 4.79 4.79 |
71%
71%
|
|
EBITDA | -69 -69 |
10%
10%
|
EBIT (Operating Income) EBIT | -70 -70 |
10%
10%
|
Net Profit | -70 -70 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
Head office | Canada |
CEO | Lindsay Androski |
Employees | 44 |
Founded | 2005 |
Website | www.arbutusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.